GSK and AstraZeneca: A leading investment bank gives its verdict with an upgrade and a downgrade

UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK is moved from 'sell' to 'buy,' while the investment bank's call on AZ moves in the opposite direction. Positivity over stock in GSK is underpinned by optimistic projections for Shingrix, its shingles vaccine. UBS anticipates Shingrix sales will outperform consensus expectations, driven by a new market opportunity i ...